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Edited by Masayuki MiyasakaAbstract Ciliary neurotrophic factor (CNTF) forms a func-
tional receptor complex containing the CNTF receptor, gp130,
and the leukemia inhibitory factor receptor (LIFR). However,
the nature and stoichiometry of the receptor-mediated interac-
tions in this complex have not yet been fully resolved. We show
here that signaling by CNTF, but not by LIF or oncostatin M
(OSM), was abolished in cells overexpressing a LIFR mutant
with the N-terminal cytokine binding domain deleted. Our re-
sults illustrate molecular diﬀerences between the CNTF active
receptor complex and those of LIF and OSM and provide fur-
ther support for the hexameric model of the CNTF receptor
complex.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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gp1301. Introduction
Ciliary neurotrophic factor (CNTF) is a member of the
gp130, or Interleukin (IL)-6, family of helical cytokines. It is
implicated in the survival of neuronal cells [1] and the forma-
tion of neuronal sprouts [2], and may have a role in the treat-
ment of amyotrophic lateral sclerosis [3]. Other ﬁndings show
that CNTF is a potential agent in the treatment of diabetes
and obesity [4] and a protective factor in demyelinating central
nervous system disease [5].
The gp130 family cytokines, CNTF, leukemia inhibitory fac-
tor (LIF), IL-6, IL-11, oncostatin M (OSM), cardiotrophin-1
(CT-1), cardiotrophin-like cytokine (CLC) and neuropoietin,
all bind either a homodimer of gp130 or a heterodimer of
gp130 and the LIF receptor (LIFR) to transduce a signal [6–
8]. CNTF, LIF, OSM, CLC and CT-1 use LIFR, although
OSM may use the OSM receptor (OSMR) instead. Moreover,
IL-6, IL-11, and CNTF must ﬁrst bind to their speciﬁc, non-
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the class I hematopoietin receptor family, which is character-
ized by the cytokine binding domain (CBD). The extracellular
region of CNTFR contains an N-terminal immunoglobulin
(Ig)-like module and a CBD, while that of gp130 is similar
but followed by three ﬁbronectin type III (FnIII) domains.
LIFR is similar to gp130 but possesses an extra, N-terminal,
copy of a CBD. The N-terminal (or membrane distal) LIFR
CBD is designated CBD1, while the other is known as CBD2.
Elucidation of the molecular details of active gp130 cytokine
receptor complexes has been a challenge due to the multiple
components and binding sites involved and the fact that either
one or two ligand molecules may be involved in the complex.
The IL-6 receptor complex was ﬁrst proposed to be a hexa-
meric complex consisting of two IL-6, IL-6R, and gp130 mol-
ecules each [9,10] although a tetrameric complex was also
postulated [11]. Subsequent studies further suggested, and later
showed, that the IL-6 complex formed by the association of
two trimers of IL-6, IL-6R, and gp130, linked by the Ig-like
domains of gp130 [12–14].
Unlike IL-6, CNTF recruits a heterodimer (LIFR and
gp130) of signaling receptors so that the interactions in its
receptor complex will be diﬀerent from those of the IL-6 com-
plex. While CNTF was reported to have a hexameric receptor
complex based on immuno-precipitation studies [15], a tetra-
meric complex has also been proposed [11]. The precise nature
of the protein–protein interactions in the CNTF receptor com-
plex remains elusive. Modeling studies [13,16] suggested that
the LIFR CBD1 was involved in an IL-6-like hexameric com-
plex, binding at site II of one of the CNTF molecules in the
hexamer while the gp130 CBD bound at site II of the other
CNTF molecule.
Our recent ﬁndings have revealed the solution structure of
the BC domain (the C-terminal FnIII domain of the CBD) of
CNTFR which is expected to be involved in receptor–recep-
tor interactions with the equivalent regions of LIFR and
gp130 [17,18]. We have also demonstrated that CNTFR
and either the CBD of gp130 or the LIFR CBD1 can form
dimers in the absence of CNTF in vitro [18,19] and that this
dimerisation is aﬀected by mutations in the BC domains of
CNTFR, gp130 and LIFR CBD1 [18]. We further showed
that the LIFR CBD1 could block signaling by CNTF in
NT-2 cells, yet signaling by LIF and IL-6 was not reduced
[19]. These ﬁndings give support to the hexameric model of
the CNTF receptor complex which predicts the interaction
of these domains.blished by Elsevier B.V. All rights reserved.
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LIF, and OSM in cytokine-LFR-gp130 complexes, we have
studied the binding of each cytokine with glutathione S-trans-
ferase (GST) fusion peptides of the CBD1, Ig-like domain, and
CBD2 of LIFR, and of the Ig-like domain and CBD of gp130
in vitro. The ability of mutants of LIFR, which either lack the
CBD1 (DCBD1) or contain point mutations within CBD1, to
transduce a signal in vivo and the ability of the receptor pep-
tides to aﬀect cytokine signaling in vivo were also analyzed.
We report here that the CBD1 of LIFR binds to CNTF and
is required for CNTF signaling. Mutations in the region of
the LIFR CBD1 expected to interact with CNTFR were found
to aﬀect CNTF signaling. In contrast, LIF and OSM did not
bind the LIFR CBD1, nor was their signaling aﬀected by its
deletion.2. Materials and methods
2.1. Plasmid construction, protein expression, refolding and puriﬁcation
for GST-LIFR and GST-gp130 fusion peptides
Human LIFR and gp130 cDNA templates were RT-PCR ampliﬁed
from mRNA of SH-SY5Y neuroblastoma cells. The DNA was se-
quenced and evaluated as previously reported [19]. BamHI and NotI
sites were introduced to the 5 0 sense and 3 0 antisense primers, the
PCR products were digested with BamHI and NotI, and ligated into
PGEX-6-p1 vector. Escherichia coli strain BL21 (DE3) cells were trans-
formed with expression vectors containing cDNA for the individual
domains. The peptides expressed were LIFR-CBD1 (49A to 246W),
Ig-like domain of LIFR (248P to 333P), LIFR-CBD2 (335T to
533A), Ig-like domain of gp130 (23E to 125P), and gp130-CBD
(125P to 321T). The procedures for induction and refolding of recom-
binant proteins and the expression and puriﬁcation of CNTFR and
CNTF were as described previously [19]. Refolded proteins were puri-
ﬁed initially with a glutathione conjugated Sepharose 4B column
(Pharmacia) and further puriﬁed by a Q Sepharose High Performance
column (Pharmacia) (Fig. 1A).Fig. 1. (A) SDS–PAGE of the GST-fusion peptides of LIFR and
gp130. (B) Schematic diagrams of the LIF receptor indicating the
location of the interferon-c sequence downstream of boxes 1 and 2 in
the cytoplasmic domain and the locations of the double alanine
mutations (DF-M, ST-M, ST 0-M, LY-M, LK-M and WN-M) in the
BC domain of CBD1 and the deletion of CBD1 (CBD1DM).2.2. GST pull-down assay and Western blot
50–300 ng of human CNTF (R&D Systems), LIF (CHEMICON
International), or OSM (R&D Systems) were allowed to incubate with
immobilized GST fusion peptides (about 600 ng on 10 ll of glutathi-
one–Sepharose beads) for 30 min at 4 C. Beads were washed six times
with PBS, then proteins on beads were dissolved in 2· SDS sample buf-
fer, separated by 12% SDS–PAGE and blotted onto nitrocellulose
membranes. Goat antibodies speciﬁc for human CNTF, LIF, OSM,
CNTFR, LIFR and gp130 (R&D Systems) at 1:1000 dilution, or for
GST (Amersham) at 1:20000 dilution, were used, as appropriate, to
identify the proteins.
2.3. Construction of human gp130 and LIFR chimeras
To generate gp130c or LIFRc constructs, a YDKPH motif, fol-
lowed by a stop-codon and a NotI site, was introduced into gp130
or LIFR DNA downstream of boxes 1 and 2 [6] via PCR. YDKPH
is a sequence motif from the Interferon-c receptor that, in its tyro-
sine-phosphorylated form, recruits STAT1 [20]. Either gp130c or
LIFRc were inserted into expression vector pMT21 or pBluescript II
KS (pB) via the XhoI and NotI sites and the DNA sequences of
pMT21-gp130c, pMT21-LIFRc, pB-gp130c and pB-LIFRc were
checked with a 310 Genetic Analyzer autosequencer.
2.4. LIFRc-CBD1 mutant constructs
LIFRc mutant constructs [D147A/F148A, S149A/T150A, S151A/
T152A, L153A/Y154A, L155A/K156A, and W157A/N158A;18], corre-
sponding to double alanine mutations in the putative AB loop and B
strand of the BC domain of LIFR CBD1, were digested with BglII
and StyI. The resulting 210 bp nucleotide sequences containing LIFR
alanine mutations were introduced into BglII/StyI-digested pB-LIFRc
plasmids. The LIFRc mutants were then subcloned into the pMT21
expression vector via XhoI and NotI sites after the sequences of the
mutations were conﬁrmed. The resulting LIFR CBD1 mutants were
designated DF-M, ST-M, ST 0-M, LY-M, LK-M and WN-M corre-
sponding to the amino acid pairs from D147 to N158 (Fig. 1B). A
pMT21 plasmid containing LIFRDCBD1, which was generated by
PCR based mutagenesis of the LIFR construct, was digested with XhoI
and DraI and the resulting 430 bp nucleotide fragment was introduced
into the XhoI and DraI sites of pB-LIFRc. The LIFRcDCBD1 was
then subcloned into the XhoI and NotI sites of the pMT21 plasmid
and designated as CBD1DM (Fig. 1B).
2.5. Transfection of 293 cells
Human 293 cells were cultured in DMEM supplemented with 10%
(v/v) FBS, 100 lg/ml of streptomycin, and 60 lg/ml of penicillin. These
cells, which endogenously express CNTFR (Ip, NY unpublished), were
transiently transfected with equal total amounts of expression vectors
encoding gp130 or gp130c, LIFR or LIFRc or the respective mutants,
and a luciferase gene reporter construct pGAS (Clontech) by applying
the lipofectamine method. Less than 1 ng of the b-galactosidase con-
trol vector (Promega) was also added. Cells transfected with the con-
structs of the luciferase reporter gene, the b-galactosidase control
vector, and gp130 and LIFR (wild-type or c) served as controls. After
48 h, transfected cells were starved in serum-free medium for 3 h, stim-
ulated with 26 ng/ml of the appropriate factor (CNTF, LIF, or OSM),
or left unstimulated. Expression of wild-type gp130, wild-type LIFR,
gp130c and LIFRc and the respective mutants, as well as STAT1 tyro-
sine phosphorylation of the stimulated cells, was analyzed by SDS–
PAGE.
2.6. Reporter gene assay in transfected 293 cells
Luciferase activity, normalized to b-galactosidase activity to correct
for transfection eﬃciency, was measured using the luciferase kit from
Promega at 6 h after treatment by the factors.
2.7. Eﬀects of exogenous LIFR and gp130 extracellular domains on
cytokine signaling in human NT-2 cells
Cells in a 35 cm dish were starved for 4 h in 1 ml of serum-free
DMEM culture medium. The LIFR CBD1, Ig-like domain, and
CBD2, and the gp130 CBD and Ig-like domain peptides were gener-
ated by removal of the GST tag after digestion with PreScission Pro-
tease (Pharmacia). The peptides were added into the culture medium
at a ﬁnal concentration of 40 nM before stimulation with cytokines.
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50 ng of CNTF, LIF, IL-6, or OSM was then applied and allowed to
incubate for 30 min. Cells were lysed in RIPA buﬀer with protease
inhibitors and 25 lg of proteins in the cell lysate was subjected to
SDS–PAGE followed by a Western blot using an anti-phospho-tyro-
sine STAT3 antibody. After stripping of membranes, total STAT3
expression was determined with an anti-STAT3 antibody.3. Results
The purity of the GST fusion peptides was shown by SDS–
PAGE (Fig. 1) and their correct folding and activity could be
inferred from the speciﬁc protein–protein interactions de-
scribed below.
3.1. In vitro interaction of CNTF, LIF and OSM with domains
of their signaling receptors
We performed an in vitro GST pull down assay to deﬁne the
domains in the extracellular region of human LIFR which
interact with CNTF, LIF and OSM. There are three diﬀerent
regions in LIFR, the N-terminal CBD (CBD1), the Ig-like do-
main and C-terminal CBD (CBD2), which might interact with
these molecules. It was shown that, in the presence of soluble
CNTFR, CNTF interacted with the LIFR CBD1 (Fig. 2A)
and (more weakly) with the LIFR Ig-like domain (Fig. 2B),
but did not interact with CBD2 (Fig. 2B). In the absence of
CNTFR a weak interaction of CNTF with the Ig-like domainFig. 2. Binding of GST fusion peptides of LIFR domains to CNTF in
the presence or absence of CNTFR. 100 or 300 ng of CNTF was
incubated with immobilized GST fusion peptides of the LIFR domains
in the presence or absence of CNTFR (200 or 300 ng) for 30 min at
4 C. After washing, peptides were separated by SDS–PAGE and
identiﬁed by Western blotting with antibodies speciﬁc for GST, CNTF
and CNTFR. (A) Interaction of GST and GST-LIFR CBD1 with
CNTF in the presence or absence of CNTFR. (B) Interaction of GST,
GST-LIFR Ig-like domain and GST-LIFR CBD2 with CNTF in the
presence or absence of CNTFR.was observed (Fig. 2B). Both LIF and OSM were found to be
able to bind to the Ig-like domain and CBD2, while no distinct
binding to CBD1 could be detected in the in vitro pull down
assay (Fig. 3).
The second signaling receptor for CNTF, LIF and OSM is
gp130 which has two regions, the Ig-like domain and the
CBD, that may interact with the cytokines. In the absence of
CNTFR, CNTF did not bind the gp130 Ig-like domain but
could bind to the gp130 CBD (Fig. 4A). When CNTFR was
present, both the Ig-like domain and CBD bound to CNTF
(Fig. 4A). OSM was able to bind to the gp130 Ig-like domain
and CBD (Fig. 4B), in contrast to LIF which failed to show
any binding to either of these domains (data not shown). How-
ever, in the presence of the LIFR Ig-like domain, LIF could
bind to the gp130 CBD (Fig. 4C) but not to the gp130 Ig-like
domain (data not shown).
3.2. Speciﬁc requirement of the LIFR CBD1 for CNTF signaling
in vivo
As only CNTF was shown to interact with the LIFR CBD1,
its role in CNTF signaling was further investigated by a lucif-
erase reporter system in transfected human 293 cells. To cir-
cumvent interference from endogenous LIFR and gp130
activity, and as full length LIFR and gp130 induced only weak
luciferase reporter activity in cells (Fig. 5), chimeric constructs
(see Section 2) LIFRc and gp130c were used. Coexpression of
LIFRc and gp130c greatly enhanced STAT1-driven luciferase
activity in cells treated with CNTF, LIF or OSM (Fig. 5).
Deletion of the LIFR CBD1 to create LIFRcDCBD1
(CBD1DM) abolished CNTF induced luciferase activity, while
signaling induced by LIF or OSM remained unchanged when
compared with that from LIFRc (Fig. 5).
Our previous report demonstrated the importance of
L155/K156 in the putative B-strand of the BC domain of LIFR
CBD1 in the ligand free interaction between the LIFR CBD1
and CNTFR [18]. As CNTF can bind to the LIFR CBD1 only
in the presence of CNTFR (Fig. 2), we predicted that the
L155A/K156A mutation in LIFR could impair CNTF signal-
ing due to the deﬁcient interaction between the LIFR CBD1
and CNTFR. Serial site-directed LIFRc mutants in the region
of CBD1 believed to bind to CNTFR were generated. A lucif-
erase reporter assay showed that the L155A/K156A mutant
(LK-M) had the strongest inhibitory eﬀect on CNTF signaling,Fig. 3. Binding of GST fusion peptides of LIFR domains to LIF and
OSM. 100–300 ng of LIF and OSM was incubated with immobilized
GST fusion peptides of the LIFR domains for 30 min at 4 C. Peptides
were separated by SDS–PAGE and identiﬁed by Western blotting with
antibodies speciﬁc for GST, LIF and OSM.
Fig. 6. Eﬀect of LIFR CBD1 mutants on signaling by CNTF and LIF.
Human 293 cells were transfected as described in the legend of Fig. 5
with LIFR, LIFR-cM or LIFRc constructs with consecutive double
alanine mutations in CBD1. The double alanine mutations (DF-M,
ST-M, ST 0-M, LY-M, LK-M and WN-M) spanned the putative AB
loop and B strand of the LIFR CBD1 BC domain (LIFR 147-
DFSTSTLYLKWN-158) that is likely to be involved in receptor–
receptor interactions. ST 0-M indicates mutation of the second ST pair
(S151/T152) in this sequence. Cells were then either not stimulated or
stimulated with CNTF or LIF. Upper panel shows the fold induction
relative to unstimulated cells. Error bars represent the S.D. of three
replicated experiments. Lower panel shows Western blots of LIFR and
the LIFRc constructs.
Fig. 4. Binding of GST fusion peptides of gp130 domains to CNTF,
LIF and OSM. Proteins were incubated with immobilized GST fusion
peptides of the gp130 domains for 30 min at 4 C. After washing,
peptides were separated by SDS–PAGE and identiﬁed by Western
blotting with antibodies speciﬁc for GST, CNTF, LIF, OSM, LIFR
and CNTFR. (A) Interaction of 100 or 300 ng of CNTF with the GST
fusion peptides of the gp130 domains in the presence or absence of
300 ng CNTFR. (B) Interaction of 50–200 ng of OSM with the GST
fusion peptides of the gp130 domains. (C) Interaction of LIF with the
GST-gp130 CBD in the presence of the LIFR Ig-like domain. LIF did
not interact with the gp130 CBD in the absence of LIFR Ig-like
domain, nor with the gp130 Ig-like domain in the presence or absence
of LIFR Ig-like domain (data not shown).
Fig. 5. Speciﬁc requirement of the LIFR CBD1 for CNTF signaling.
Human 293 cells were transfected with a luciferase reporter construct
and with LIFR and gp130 or with chimeric constructs of gp130
(gp130c) and LIFR with or without CBD1 deleted (LIFR-cM,
CBD1DM). Cells were then either not stimulated or stimulated with
CNTF, LIF or OSM. Upper panel shows the fold induction relative to
unstimulated cells. Error bars represent the S.D. of three replicated
experiments. Lower panel shows Western blots of the LIFR and gp130
constructs.
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fect on LIF induced luciferase activity when compared with
activity induced through wild-type LIFRc (Fig. 6).
3.3. Eﬀect of the LIFR and gp130 peptides on CNTF, LIF, IL-6
and OSM signaling in vivo
As shown in our earlier work, the LIFR CBD1 could block
signaling by CNTF but not that by LIF or OSM in NT-2 cells,
which endogenously express CNTFR, LIFR and gp130 [19]. In
light of that ﬁnding and the in vitro results described above,
the LIFR and gp130 peptides were tested for their ability to in-
hibit signaling by CNTF, LIF, IL-6 and OSM in NT-2 cells
in vivo. A representative experiment is shown (Fig. 7A) and
the average results of three independent experiments are de-
picted in Fig. 7B. The LIFR CBD1 blocked signaling by
CNTF but not that by LIF, IL-6 or OSM (Fig. 7B). Consistent
with the in vitro binding data (Figs. 2 and 3), both the LIFR
Ig-like and CBD2 peptides blocked LIF and OSM signaling,
however these peptides did not aﬀect IL-6 signaling(Fig. 7B). The gp130 CBD inhibited signaling by all the cyto-
kines while the gp130 Ig peptide only blocked IL-6 and CNTF
signaling (Fig. 7B).4. Discussion
New roles for CNTF in neuronal diseases, diabetes and
obesity have been emerging recently [1–5]. Coupled with the
Fig. 7. Eﬀects of exogenous LIFR and gp130 extracellular peptides on
CNTF, LIF, IL-6 and OSM signaling. Human NT-2 cells were starved
in serum free medium for 4 h before addition of the diﬀerent peptides.
Cells were then treated with diﬀerent cytokines for 30 min. (A) Western
blot analysis of total cell lysates after cytokine treatment. Blots were
probed with an anti-phospho-STAT3 or an anti-STAT3 antibody. (B)
Statistical analysis of the relative band intensities from the Western
blot analyses. Results are the means ± S.D. of three independent
experiments.
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CNTFR [7,8] knowledge of the interactions among CNTF and
its receptors will help in understanding the functions of these
molecules and in developing them as therapeutic agents. In this
work, we have further elucidated the roles of the regions in
LIFR and gp130 in CNTF binding and signaling.
Evidence for the speciﬁc and essential role of the LIFR
CBD1 for CNTF binding and downstream signaling has been
presented. In vitro binding assays showed that the LIFR
CBD1 could pull down CNTF in the presence of CNTFR,
whereas LIF and OSM did not interact with this peptide. A
weaker interaction was observed between CNTF and theLIFR Ig-like domain. However, no interaction was seen be-
tween CNTF and the LIFR CBD2. In contrast, both these
LIFR receptor domains bound to LIF and OSM, with the
LIFR Ig-like domain showing stronger binding. This demon-
strated a role for the LIFR CBD1 in CNTF binding and that
the interactions of CNTF with LIFR are diﬀerent from those
of LIF and OSM.
The importance of the LIFR CBD1 in formation of the
active CNTF receptor complex was demonstrated by
in vivo luciferase reporter assays in human 293 cells, which
endogenously express CNTFR and were transfected to
express LIFR (or its mutants) and gp130. A LIFR mutant
with the CBD1 deleted (LIFRcDCBD1–CBD1DM) failed
to respond to CNTF stimulation. Structural destabilization
of LIFRcDCBD1 did not occur, since the molecule could
still make the appropriate interactions with LIF and OSM
as their signaling was not aﬀected. Mutations in the LIFR
CBD1 that were found earlier to aﬀect LIFR–CNTFR inter-
actions in vitro [18] also inhibited CNTF signaling in vivo
while having no eﬀect on LIF signaling. These results show
that the LIFR CBD1 is required for CNTF signaling and
support its interaction with CNTF and CNTFR in a manner
consistent with that of the proposed hexameric signaling
complex [18] where the LIFR CBD1 is suggested to bind
CNTF at site II.
Binding to gp130 domains also diﬀered among the cyto-
kines. CNTF bound strongly to both the gp130 Ig-like domain
and the CBD. OSM was also able to bind both these modules,
although binding to the Ig-like domain was weaker. Neither of
the gp130 domains was able to bind to LIF in the absence of
LIFR. In the presence of the LIFR Ig-like domain, binding
of LIF to the gp130 CBD, but not to the gp130 Ig-like domain,
was observed. It has previously been shown that the gp130 Ig-
like domain is not required for either LIF or OSM signaling
[21]. Our in vitro pull down assays showed no substantial dif-
ferences in the binding of the gp130 CBD to LIF (in the pres-
ence of LIFR), OSM and CNTF.
Binding of LIF to gp130 in the absence of LIFR has been
observed previously through cross-linking studies [22] and
under crystallization conditions and using isothermal titration
calorimetry [23]. However, similar to our results, a LIF-gp130
interaction was not seen under native PAGE and gel-ﬁltration
chromatography [24]. Cross-linking showed a 1:1 complex and
surface plasmon resonance revealed low aﬃnity binding with a
high dissociation rate [24], which is consistent with our inabil-
ity to observe an interaction between LIF and gp130 in our
experiments.
A trimeric complex for LIF and its receptors, LIFR and
gp130, has been identiﬁed [24]. Several lines of evidence,
based on chimeric receptors and site-directed mutagenesis,
indicated that the Ig-like domain of LIFR was involved in
both LIF and OSM binding and signaling [25–28]. These
studies suggested that site III of LIF binds to the LIFR
Ig-like domain. Possible roles for the CBD1 and for site I
of LIF having a weaker interaction with CBD2 were also
proposed [26]. These ﬁndings are consistent with our results,
except that the LIFR CBD1 does not appear to have a role
in LIF binding or signaling.
The Ig-like domain of LIFR was shown here to bind LIF,
OSM and CNTF (in the presence or absence of CNTFR)
and the gp130 Ig-like domain was shown to bind OSM and
CNTF. Earlier, and in this work, it was shown that, despite
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quired for OSM signaling [21]. Binding to CNTF by the Ig-like
domain of LIFR in the active CNTF receptor complex is
incompatible with the role of the LIFR CBD1 shown here.
The abolition of CNTF signaling by deletion of the LIFR
CBD1 and the eﬀect on signaling of LIFR CBD1 mutants sug-
gest that the LIFR Ig-like domain may not be implicated in
CNTF signaling. This was supported by the very slight inhibi-
tion of CNTF signaling caused by the LIFR Ig-like domain. It
may be that binding of isolated receptor Ig-like domains may
reﬂect a common ability of these domains to bind to site III of
the LIFR binding members of gp130 cytokine family through
the conserved FXXK motif and not necessarily reﬂect a func-
tional role.
It was suggested previously that two residues in site III of
CNTF may aﬀect LIFR binding [29]. However, structural
destabilization of CNTF by these mutations could not be
excluded as the individual mutations did not necessarily
aﬀect CNTF signaling and the double mutant did not antag-
onize the biological eﬀects of wild-type CNTF [29]. A
mutant of LIF, that could not bind gp130, has been shown
to antagonize LIFR dependent signaling by LIF, CT-1,
OSM and CNTF [30]. One possible explanation could be
that these ligands bound LIFR at the same location and
competed with the mutant LIF molecule for that site. How-
ever, antagonism of CNTF binding would still be possible if
CNTF bound LIFR through a site diﬀerent from that used
by LIF, as proposed here. Binding of LIFR by LIF, at
probably the Ig-like domain, may alter the conformation
of the receptor and so prevent binding by another molecule.
However, a LIF molecule bound to LIFR at the Ig-like do-
main would, by steric hindrance, be very likely to prevent
either other molecules from binding to the other receptor
domains at the same time or the formation of the complete
receptor complex.
Given the binding interactions of the receptor peptides de-
scribed above, it would be expected that they would have
diﬀering eﬀects on the biological activity of the cytokines.
Earlier we showed that the LIFR CBD1 inhibited signaling
by CNTF but not that by LIF or IL-6 [19]. In this work
that result was replicated and the eﬀect of all the receptor
peptides on CNTF, LIF, IL-6 and OSM signaling in vivo
was investigated. CNTF signaling was blocked by the LIFR
CBD1 and the gp130 Ig-like domain and gp130 CBD. It was
not aﬀected by the LIFR CBD2 and a slight eﬀect was seen
for the LIFR Ig-like domain. These interactions are consis-
tent with the hexameric complex of CNTF and its receptors
[16,18].
Signaling by LIF was inhibited by the LIFR Ig-like domain
and the gp130 CBD. Some inhibition from the LIFR CBD2
was observed, however there was no eﬀect from the gp130
Ig-like domain and the LIFR CBD1 did not inhibit LIF signal-
ing. These results are consistent with the trimeric complex and
ligand–receptor interactions proposed for LIF [24–28]. Consis-
tent with the interactions seen from the crystal structure of IL-
6 with its receptors [14], IL-6 signaling was inhibited by both
gp130 peptides but not those of LIFR. OSM signaling was re-
duced by the LIFR Ig-like and CBD2 domains and the gp130
CBD but not by the gp130 Ig-like domain or the LIFR CBD1,
consistent with earlier studies [21,23]. The interactions of the
peptides studied here are consistent with the known ligand–
receptor interactions of LIF, IL-6 and OSM.As in our previous study [19], it was found that the LIFR
CBD1 actually enhanced signaling from LIF, IL-6 and
OSM. One possible reason for this may be due to the ligand
free interaction between the LIFR CBD1 or the gp130 CBD
and CNTFR reported earlier [18,19]. Binding of the LIFR
CBD1 to cellular CNTFR may prevent cellular CNTF from
competing for binding to cellular LIFR and gp130, thus mak-
ing more signaling receptors available to the other cytokines.
As a consequence of the greater number of free gp130 mole-
cules, increased responsiveness of NT-2 cells to IL-6 would
be expected, while increased availability of both gp130 and
LIFR would similarly increase responsiveness to LIF and
OSM as we observed.
Our ﬁnding of the critical role of the LIFR CBD1 in CNTF
signaling is consistent with a hexameric model for the CNTFR
complex where the LIFR CBD1 binds CNTF at site II
[13,16,18]. CNTF might form two trimers, one with CNTFR
and LIFR and the other with CNTFR and gp130. The interac-
tion with LIFR would be through CBD1, consistent with its
requirement for CNTF signaling reported here and that of
models of the LIFR CBD1 that showed it had a similar elec-
trostatic proﬁle to the gp130 CBD [18]. One possible linkage
of two trimers of CNTF, CNTFR and either LIFR or gp130
is through the interaction between the site III of one molecule
of CNTF and the Ig-like domain of gp130 as seen in the IL-6
receptor complex [14]. The diﬀerential role of the LIFR CBD1
found here may allow the design of agents that can speciﬁcally
inhibit LIF and OSM signaling while leaving CNTF signaling
unaﬀected, or vice versa.
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